 Home > Active Ingredient News > Antitumor Therapy > Avasopasem for treatment of severe oral mucositis induced by radiotherapy, the phase III ROMAN trial failed to reach the primary endpoint

Avasopasem for treatment of severe oral mucositis induced by radiotherapy, the phase III ROMAN trial failed to reach the primary endpoint

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

approved biosimilars fda

makeup cause cancer

endometriosis clinical trial

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Oral mucositis is a side effect of radiotherapy and is characterized by severe pain, inflammation, ulcers, and oral bleeding
.

For patients with head and neck cancer, radiotherapy is the main treatment method

prevention

Galera Therapeutics, a clinical-stage biopharmaceutical company, today announced the results of the avasopasem phase III ROMAN trial, which evaluated avasopasem treatment of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) who received standard radiotherapy.
However, the trial did not reach the primary endpoint of reducing the incidence of SOM
.

The results of the Phase III ROMAN trial of avasopasem were announced today.
The trial evaluated severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) who received standard radiotherapy with avasopasem.
However, the trial did not reach the main point of reducing the incidence of SOM.
The end
.

The results of the Phase III ROMAN trial of avasopasem were announced today.

FDA

The main findings of the OMAN trial include:

Compared with the placebo group (64%) in the avasopasem treatment group (54%), the incidence of SOM was relatively reduced by 16% (p=0.

Original source:
Original source:
https:// href="https://" target="_blank" rel="noopener">https:// https:// leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

N-Desmethyl Imatinib 99%

CAS No.: 404844-02-6

Pharma Grade

$1/MT FOB

High purity Octenidine dihydrochloride 98% with best price 70775-75-6 and Octenidine dihydrochloride raw material

CAS No.: 70775-75-6

Pharmacy Grade

$8.8-10/MT FOB

Anti-Cancer Pirespa Powder CAS 53179-13-8 Pirfenidone 5-methyl-1-phenylpyridin-2-one

CAS No.: 53179-13-8

Pharmacy Grade

$4/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.